A marker of asthma inflammation: Orally exhaled nitric oxide

Michela Silvestri, Federica Sabatini, Anna Carla Defilippi, Laura Ghiro, Eugenio Baraldi, Giovanni A. Rossi

Research output: Contribution to journalArticle

Abstract

Bronchial inflammation is a key feature of asthma since mediators released by inflammatory cells may induce acute damages and structural changes to the airways. Airway inflammation is, therefore, a primary therapeutic goal and that treatment with anti-inflammatory drugs should be started as early as possible, when needed. The need to monitor inflammation has led to the exploration of exhaled gases. In the last years, several reports have demonstrated that increased nitric oxide (NO) is present in the expired air of patients with asthma and that measurement of the fractional concentration of exhaled NO (FENO) may represents a non invasive, simple, well tolerated test thought to reflect the airway inflammatory events in asthmatic patients.

Original languageEnglish
Pages (from-to)37-43
Number of pages7
JournalAllergy and Clinical Immunology International
Volume15
Issue number1
Publication statusPublished - Jan 2003

ASJC Scopus subject areas

  • Immunology and Allergy

Fingerprint Dive into the research topics of 'A marker of asthma inflammation: Orally exhaled nitric oxide'. Together they form a unique fingerprint.

  • Cite this